Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
47 hedge funds and large institutions have $285M invested in Surface Oncology, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
+$67.2M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$48M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.6M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$12.9M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$12.8M |
Top Sellers
SURF Hedge Fund Activity: Q2 2018 in Review
47 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q2 2018, worth a combined $285M.
Buyers outnumbered sellers: 47 funds opened new SURF positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Atlas Venture Associates IX, opening a new position worth an estimated $67.2M.
- 47 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q2 2018, up from 0 in Q1 2018.
- Funds reported $285M of Surface Oncology, Inc. Common Stock stock for Q2 2018.
- 47 funds opened new Surface Oncology, Inc. Common Stock positions in Q2 2018 and 0 closed out, a net change of +47 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q2 2018 was Atlas Venture Associates IX, an estimated $67.2M added.
Based on aggregated 13F filings for Q2 2018.